Ernst, Thomas <br/><br/>
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.  [electronic resource] 

 -  Haematologica  Sep 2009 
 - 1227-35 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.2009.006981  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Benzamides<br/>DNA Mutational Analysis<br/>Dasatinib<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Fusion Proteins, bcr-abl--antagonists & inhibitors<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Piperazines--administration & dosage<br/>Polymerase Chain Reaction<br/>Protein Kinase Inhibitors--administration & dosage<br/>Protein Structure, Tertiary--genetics<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyrimidines--administration & dosage<br/>Thiazoles--administration & dosage